Dr Reddy’s Pins Hopes On Complex Drugs Pipeline Amid Weak Q3

Dr Reddy’s Laboratories is betting on complex product launches to power an improvement in its bottom line after reporting a 29% drop in quarterly net profit, hit by price erosion in its main US market.